Graser C, McDonald TO, Catalano PJ, Sonpavde G, Michor F. Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao . Journal for immunotherapy of cancer. 2025;13(6). doi:10.1136/jitc-2025-012742